Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

Molecular Psychiatry

Volumn 7, Issue 10, 2002, Pages 1115-1119

  Yu, Y W Y ^a   Tsai, S J ^b,c   Chen, T J ^d   Lin, C H ^d   Hong, C J ^b,c  

^a Yu's Psychiatric Clinic   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

Author keywords

Major depressive disorders; Polymorphism; Selective serotonin reuptake inhibitors; Serotonin transporter; Treatment response

Indexed keywords

FLUOXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLELE; ANXIETY; ARTICLE; CHINESE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROMOTER REGION; RATING SCALE; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; CARRIER PROTEINS; CHINA; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0036931893     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001141     Document Type: Article

References (25)

1. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000; 61 Suppl 2: 10-12.
2. Cleare AJ, Murray RM, O'Keane V. Assessment of serotonergic function in major depression using d-fenfluramine: Relation to clinical variables and antidepressant response. Biol Psychiatry 1998; 44: 555-561.
3. Lucini V, Lucca A, Catalano M. Smeraldi E. Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. J Affect Disord 1996; 36: 129-133.
4. Sallee FR, Nesbitt L, Dougherty D, Hilal R, Nandagopal VS, Sethuraman G. Lymphocyte glucocorticoid receptor: Predictor of sertraline response in adolescent major depressive disorder (MDD). Psychopharmacol Bull 1995: 31: 339-345.
5. Ko HC, Lu RB, Shiah IS, Hwang CC. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biol Psychiatry 1997; 41: 774-781.
6. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624.
7. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenherg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-15231.
8. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729-738.
9. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T et al. Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2: 457-462.
10. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
11. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
12. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-157.
13. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
15. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
16. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624.
17. Serretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E. Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry 1999; 4: 280-283.
18. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R. Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
19. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001; 6: 258-259.
20. Zohar J, Westenberg HG. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 39-49.
21. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215-235.
22. Gobbi G, Murphy DL, Lesch KP, Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: An in vivo electrophysiological study. J Pharmacol Exp Ther 2001; 296: 987-995.
23. Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, Lesch KP et al. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 2000; 12: 2299-2310.
24. Gingrich JA, Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 2001; 155: 1-10.
25. Burke WJ, Hendricks SE, McArthur-Campbell D, Jacques D, Stull T. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol Bull 1996; 32: 27-32.